Metformin for Premature Infants With Bronchopulmonary Dysplasia
Recruiting now · Early Phase 1
Conditions studied: Bronchopulmonary Dysplasia (BPD)
In brief
The overall objective of this study is to investigate the role of metformin in decreasing lung injury and promoting lung growth in premature infants. There are two phases to this pilot study. For Phase 0, the goal is to investigate the safety and tolerance of oral metformin in premature who have been diagnosed with bronchopulmonary dysplasia (BPD) at 36-44 weeks gestation. For Phase 1, the goal is to investigate metformin safety and tolerance in extremely premature infants who are 7-30 days old who have an increased risk of BPD. The main questions it aims to answer are: * how well do older premature infants tolerate metformin? * how well do younger premature infants tolerate metformin?
Key facts
- Study ID
- NCT07120971
- Run by
- Medical College of Wisconsin
- People needed
- 40
- Starts
- 2025-12-19
- Expected to finish
- 2030-09-01
- Last updated by the study team
- 2026-01-26
Who can join
Age: 0 and older, up to 1. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- Persistent hypoglycemia
- Lactic acidosis
- Feeding intolerance
- Renal or hepatic dysfunction
- Active infection
- Congenital anomalies that preclude feedings
- Infants whose parents have chosen palliative care
Where it is running
- Children's Wisconsin — Milwaukee, Wisconsin, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.